EUVIMEDEUVIMED entdecken
Übersichtsarbeit

FGFR rearrangements: oncogenic drivers and therapeutic targets

Julia Yemelyanenko, Jos Jonkers, Daniel Zingg

Trends in Cancer · 2026-05 · 12 (5) · 461-476

DOI: 10.1016/j.trecan.2026.01.010 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Trends in Cancer, 2026-05. Verfasst von Julia Yemelyanenko und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands. Hauptthemen laut MEDLINE: Neoplasms, Receptors, Fibroblast Growth Factor, Gene Rearrangement. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 105 Literaturangaben. Gefördert von: Oncode Institute, Netherlands Ministry of Health Welfare and Sport, Dutch Cancer Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Genomic amplifications and hotspot mutations affecting fibroblast growth factor receptors (FGFRs) have long been recognized as oncogenic drivers across human cancers. However, recent studies have uncovered FGFR in-frame fusions and complex structural variants as an additional class of tumor driver alterations. Notably, the identification of FGFR2 exon 18 truncations and the demonstration of their potent oncogenic competence have refined our understanding of FGFR-driven tumorigenesis and have impacted clinical trial design for FGFR-targeted agents. This review explores the biological and clinical implications of FGFR rearrangements. It covers their mechanisms in driving cancer, their potential as biomarkers to predict treatment response, and the emerging challenges and opportunities for FGFR-targeted therapy. Ultimately, a deeper understanding of FGFR rearrangements is critical for advancing precision oncology and improving patient benefit.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsReceptors, Fibroblast Growth FactorGene RearrangementHumansMolecular Targeted TherapyAnimalsProtein Kinase InhibitorsBiomarkers, TumorAntineoplastic AgentsOncogene Proteins, Fusion

Stichwörter der Autor:innen

FGFRFGFR inhibitorsgene fusionsgene rearrangementstargeted therapy

Substanzen

Receptors, Fibroblast Growth FactorProtein Kinase InhibitorsBiomarkers, TumorAntineoplastic AgentsOncogene Proteins, Fusion

Autor:innen und Institutionen

  • Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands.
  • Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands. Electronic address: j.jonkers@nki.nl.
  • Department of Discovery Oncology, Genentech, Inc., South San Francisco, CA, USA. Electronic address: zingg.daniel@gene.com.

Förderung

  • Oncode Institute
  • Netherlands Ministry of Health Welfare and Sport
  • Dutch Cancer Society

Zitieren

APA

Yemelyanenko, J., Jonkers, J., & Zingg, D. (2026). FGFR rearrangements: oncogenic drivers and therapeutic targets. Trends in Cancer, 12(5), 461-476. https://doi.org/10.1016/j.trecan.2026.01.010

Vancouver

Yemelyanenko J, Jonkers J, Zingg D. FGFR rearrangements: oncogenic drivers and therapeutic targets. Trends in Cancer. 2026;12(5):461-476. doi:10.1016/j.trecan.2026.01.010

BibTeX
@article{Yemelyanenko2026,
  author = {Yemelyanenko, Julia and Jonkers, Jos and Zingg, Daniel},
  title = {FGFR rearrangements: oncogenic drivers and therapeutic targets},
  journal = {Trends in Cancer},
  year = {2026},
  volume = {12},
  number = {5},
  pages = {461--476},
  doi = {10.1016/j.trecan.2026.01.010}
}
Kostenlos starten →